Market Place
Sourcing Support
MAIA Bio Closes $30M Public Stock Offering
04 Mar 2026 //
GLOBENEWSWIRE
Maia Biotech reports positive Phase 2 THIO-101 trial update
05 Jun 2025 //
BUSINESSWIRE
MAIA Biotechnology to Present Poster at ASCO 2025 Annual Meeting
15 May 2025 //
BUSINESSWIRE
MAIA Highlights 2024 Achievements, Anticancer Progress
07 Jun 2024 //
BUSINESSWIRE
FDA Telomerase Approval Shows Viability Of MAIA`s Telomere Approach
07 Jun 2024 //
BUSINESSWIRE
MAIA Highlights Novel Anticancer Agent Progress In 2024
06 Jun 2024 //
BUSINESSWIRE
MAIA Bio: THIO Efficacy In Non-Small Cell Lung Cancer
04 Jun 2024 //
BUSINESSWIRE
MAIA Announces Director`s Share Purchase In Private Placement
30 Apr 2024 //
BUSINESSWIRE
MAIA Bio Director Stan Smith Ph.D. Participates in Private Placement
29 Apr 2024 //
BUSINESSWIRE
MAIA Biotechnology Announces $1.00 Million Private Placement
23 Apr 2024 //
BUSINESSWIRE
MAIA Biotechnology to Present at Two Investor Conferences in April 2024
05 Apr 2024 //
BUSINESSWIRE
MAIA Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero
28 Mar 2024 //
BUSINESSWIRE
MAIA Announces Share Purchase by Director Adelina Louie in Private Placement
26 Mar 2024 //
BUSINESSWIRE
MAIA Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap
21 Mar 2024 //
BUSINESSWIRE
MAIA Biotechnology to Participate in the 36th Annual ROTH Conference
07 Mar 2024 //
BUSINESSWIRE
MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates
05 Mar 2024 //
BUSINESSWIRE
MAIA Appoints Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor
27 Feb 2024 //
GLOBENEWSWIRE
MAIA Announces Publication on Effects of THIO for Small Cell Lung Cancer
07 Feb 2024 //
BUSINESSWIRE
MAIA Bio Provides Positive Phase 2 Clinical Updates for Anticancer Agent
17 Jan 2024 //
BUSINESSWIRE
MAIA Biotechnology Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
BUSINESSWIRE
MAIA Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer
24 Oct 2023 //
BUSINESSWIRE
MAIA Bio to Present Preliminary Safety Data from THIO-101 Phase 2 Trial
19 Oct 2023 //
BUSINESSWIRE
MAIA Bio to Present Findings for Second Generation THIO Program
17 Oct 2023 //
BUSINESSWIRE
MAIA Biotechnology Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
BUSINESSWIRE
MAIA Reports Updates on Disease Control Rates for THIO-101 Phase 2 Trial
11 Jul 2023 //
BUSINESSWIRE
MAIA Reports Updates on Preliminary Survival Data for THIO-101 Phase 2 Trial
10 Jul 2023 //
BUSINESSWIRE
MAIA Bio Files Second Patent For New Telomere-Targeting Molecules Program
07 Jun 2023 //
BUSINESSWIRE
MAIA Biotechnology Reports First Quarter 2023 Financial Results
08 May 2023 //
BUSINESSWIRE
MAIA Reports Data from THIO-101 PII Trial for Non-Small Cell Lung Cancer
11 Apr 2023 //
BUSINESSWIRE
MAIA Biotechnology Reports Full Year 2022 Financial Results
24 Mar 2023 //
BUSINESSWIRE
MAIA Biotechnology to Participate in Four Upcoming Investor Conferences
05 Jan 2023 //
BUSINESSWIRE
MAIA Holds Successful Pre-IND Meeting with FDA for Expansion of THIO-101
20 Dec 2022 //
BUSINESSWIRE
MAIA receives approval for NSCLC therapy trial in Europe
14 Dec 2022 //
CLINICALTRIALSARENA
MAIA Biotechnology Expands Phase 2 THIO-101 Trial to Europe
13 Dec 2022 //
BUSINESSWIRE
MAIA Biotechnology Announces Establishment of Rule 10b5-1 Trading Plan
22 Nov 2022 //
BUSINESSWIRE
MAIA Biotech Presents Data at SITC Annual Meeting Validating Efficacy of THIO
15 Nov 2022 //
BUSINESSWIRE
MAIA Biotechnology Reports 3Q 2022 Financial Results &Provides Corporate Update
09 Nov 2022 //
BUSINESSWIRE
MAIA Biotechnology to Participate in ThinkEquity Conference
06 Oct 2022 //
BUSINESSWIRE
MAIA to Present at EORTC-NCI-AACR Symposium on Molecular Targets
29 Sep 2022 //
BUSINESSWIRE
MAIA to Participate in H.C. Wainwright 24th Annual Global Investment Conference
08 Sep 2022 //
BUSINESSWIRE
MAIA Biotechnology to Present Design of THIO-101 Trial at ESMO Congress 2022
06 Sep 2022 //
BUSINESSWIRE
MAIA to Present Anticancer THIO Platform at International Round Table
30 Aug 2022 //
BUSINESSWIRE
MAIA Biotechnology Reports Second Quarter 2022 Financial
22 Aug 2022 //
PRESS RELEASE
MAIA Biotechnology Reports Second Quarter 2022 Financial Results
22 Aug 2022 //
BUSINESSWIRE
MAIA Biotech Receives FDA ODD for THIO for the Treatment of SCLC
02 Aug 2022 //
BUSINESSWIRE
MAIA Biotechnology Announces Closing of Initial Public Offering
01 Aug 2022 //
BUSINESSWIRE
MAIA Biotechnology Announces Pricing of Initial Public Offering
27 Jul 2022 //
BUSINESSWIRE
MAIA Biotechnology Doses First Patient With THIO in PII Trial (THIO-101)
18 Jul 2022 //
BUSINESSWIRE
MAIA Bio Establishes Wholly Owned Subsidiaries in Romania and Australia
19 May 2022 //
BUSINESSWIRE
MAIA Bio Announces FDA ODD for THIO for Hepatocellular Carcinoma
26 Apr 2022 //
BUSINESSWIRE
MAIA Bio, Inc. says $2.4 M Financing to Advance Targeted Immuno-Oncology Studies
16 Mar 2022 //
BUSINESSWIRE
MAIA Biotechnology Appoints Steven M. Chaouki to Its Board of Directors
28 Sep 2021 //
BUSINESSWIRE
MAIA Biotechnology, Inc. Announces Formation of Scientific Advisory Board
15 Sep 2021 //
BUSINESSWIRE
MAIA Biotechnology appoints Joseph F. McGuire as CFO; provides Corporate Update.
17 Aug 2021 //
BUSINESSWIRE
MAIA Biotechnology, Inc. Announces Additions to Executive Team
05 Aug 2021 //
BUSINESSWIRE
MAIA Biotechnology, Inc. Announces Additions to Executive Team
04 Aug 2021 //
BUSINESSWIRE
MAIA Biotechnology, Inc. Raises $8.0 Million Financing to Advance Pipeline
18 May 2021 //
BUSINESSWIRE
MAIA Biotechnology, Inc. Announces Clinical Supply Agreement with Regeneron
02 Feb 2021 //
BUSINESSWIRE
